ATHA
Athira Pharma Inc
A biopharmaceutical company that develops small-molecule therapies to repair and protect brain cells in people with neurodegenerative diseases. It was founded in 2011 as M3 Biotechnology and renamed Athira Pharma in 2019, taking its name from the Arabic word "athir," meaning "a force" or "an energy." In early 2026 the company rebranded to LeonaBio and expanded into oncology, licensing a breast-cancer drug candidate while continuing to develop its experimental brain therapy ATH-1105.
CUSIP: 04746L104HealthcareUS1 holder